Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fulminant hepatic failure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Fulminant hepatic failure. Displaying page 1 of 1.
    EudraCT Number: 2010-020657-14 Sponsor Protocol Number: ALF-5755_P2_ALF Start Date*: 2011-07-04
    Sponsor Name:Alfact Innovation
    Full Title: A multicentre, double-blind, randomized, placebo-controlled study to evaluate the efficacy and the safety of ALF-5755 in patients with nonacetaminophen severe acute hepatitis and early stage acute ...
    Medical condition: Acute liver failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10049844 Acute liver failure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000837-39 Sponsor Protocol Number: CCD01 Start Date*: 2007-08-15
    Sponsor Name:Cytonet GmbH & Co. KG
    Full Title: Open, randomized, prospective, controlled, multicentre study to evaluate the efficacy and safety of multiple intraportal applications of liver cell suspension in patients with acute liver failure n...
    Medical condition: Acute Liver Failure Subgroups of patients with indications falling under ICD classification codes:K70.4, K71, K72, K75, K76, K77
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049844 Acute liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000316-29 Sponsor Protocol Number: 3571 Start Date*: Information not available in EudraCT
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Hepatocytes co-encapsulated with mesenchymal stromal cells in alginate microbeads for the treatment of acute liver failure in paediatric patients: HELP study
    Medical condition: Acute liver failure in paediatric patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10049844 Acute liver failure LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001177-32 Sponsor Protocol Number: HEP101 Start Date*: 2016-08-09
    Sponsor Name:Promethera Biosciences
    Full Title: Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with Acute on Chronic Liver Failure
    Medical condition: The study will recruit cirrhotic patients who are hospitalized for Acute-on-chronic liver failure (ACLF) or Acute Decompensation at risk of developing ACLF. ACLF combines an acute deterioration of...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10008954 Chronic liver disease and cirrhosis LLT
    20.1 100000004871 10049844 Acute liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-003989-27 Sponsor Protocol Number: PROLONGSTEM Start Date*: Information not available in EudraCT
    Sponsor Name:Promethera Therapeutics
    Full Title: PROLONGSTEM: HepaStem Long-Term Safety Registry Registry for patients who have been administered HepaStem
    Medical condition: This study will include all patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HALPC during a previous interventional clinical study conducted by...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10021601 Inborn error of metabolism NOS LLT
    20.0 100000004871 10008954 Chronic liver disease and cirrhosis LLT
    20.1 100000004871 10049844 Acute liver failure LLT
    21.1 200000003094 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003023-20 Sponsor Protocol Number: UCL-PLTP-002 Start Date*: 2008-09-11
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: TACROLIMUS – DACLIZUMAB - MYCOPHENOLATE MOFETIL IMMUNE PROPHYLAXIS IN PEDIATRIC LIVER TRANSPLANTATION. An open, pilot, investigator-driven study in 20 recipients
    Medical condition: Liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024678 Liver failure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001822-81 Sponsor Protocol Number: TJT1106 Start Date*: 2011-09-06
    Sponsor Name:CHU-Ulg
    Full Title: Infusion of third-party mesenchymal stem cells after renal or liver transplantation: a phase I-II, open-label, clinical study.
    Medical condition: Liver failure: end-stage liver diseases, including cirrhosis, primary liver cancer, fulminant hepatic failure and numerous other metabolic or congenital hepatic diseases. Kidney failure: end-st...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10050434 Prophylaxis against liver transplant rejection LLT
    14.0 10042613 - Surgical and medical procedures 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 22:35:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA